中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系

doi:10.6040/j.issn.1671-7554.0.2016.446

摘要/Abstract

摘要： 目的探讨果蝇zeste增强子同源物2(EZH2)蛋白在中国尤文肉瘤(EWS)患者中的表达与临床病理参数特征及预后的关系。方法收集67例尤文肉瘤/原始神经外胚层肿瘤(EWS/PNET)和其他小圆细胞恶性肿瘤石蜡标本并构建组织芯片,采用荧光原位杂交(FISH)法检测尤文肉瘤断裂位点1(EWSR1)基因易位;应用免疫组织化学法检测肿瘤组织标本中EZH2、Ki-67和P53的表达;应用Kaplan-Meier(K-M)和Cox多因素分析法进行生存分析。结果确诊EWS石蜡组织标本44例;EZH2蛋白在EWS组织中的高表达与肺转移及预后密切相关(P=0.023, P=0.004),并且与Ki-67表达呈正相关性(R=0.406, P=0.006)。EZH2高表达和高Ki-67增殖指数与患者不良预后呈显著相关性(P=0.006, P=0.023);Cox多因素分析表明,P53的表达与EWS患者的总体生存差异无统计学意义(P>0.05),但EZH2和Ki-67是影响患者总体生存的独立预后判定因子(HR=3.467, 95%CI=1.138~10.563, P=0.029; HR=2.140, 95%CI=0.439~10.423, P=0.046)。进一步分析显示,EZH2和Ki-67同时高表达的亚群生存期最短(P=0.012)。结论 EZH2和Ki-67的表达是EWS患者的独立预后因素,并且EZH2和Ki-67的联合检测可以识别预后极差的一部分EWS患者,EZH2可能是EWS新的预后标志物。

关键词: 临床病理学, zeste增强子同源物2, 预后, 免疫组织化学法, 尤文肉瘤, Ki-67

Abstract: Objective To explore the expression of enhancer of zeste homolog 2(EZH2)in Chinese Ewing sarcoma(EWS)patients, and to analyze its correlation with the clinicopathological parameters and prognosis. Methods Tissues from 67 cases of Ewing sarcoma/primitive neuroectodermal tumor(EWS/PNET)and other small round cell malignant tumors were collected and microarrayed. Gene rearrangement in EWS region 1(EWSR1)was evaluated using fluorescence in situ hybridization(FISH). The expressions of EZH2, P53 and Ki-67 were determined using immunohistochemical method. Survival analysis was performed with Kaplan-Meier and Cox method. Results A total of 44 cases were confirmed EWS. EZH2 expression was closely related to lung metastasis(P=0.023)and prognosis(P=0.004)in EWS tissues, and positively correlated to the expression of Ki-67(R=0.406, P=0.006). There was significant correlation between poor prognosis and high expression of EZH2(P=0.06)and high proliferation index of Ki-67(P=0.023). Cox multivariate analysis revealed that there was no significant correlation between P53 expression and overall survival(P>0.05); EZH2 and Ki-67 were independent risk factors for overall survival(HR=3.467, 95%CI=1.138-10.563, P=0.029; HR=2.140, 95%CI=0.439-10.423, P=0.046). In addition, a subset of EWS patients with overexpression of both EZH2 and Ki-67 had the shortest survival time (P=0.012). Conclusion EZH2 and 山东大学学报 (医学版)55卷2期 -张希英,等.中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系 \=-Ki-67 are independent prognostic factors in Chinese EWS patients. A combined detection of EZH2 and Ki-67 can help to identify the subset with extremely poor prognosis. EZH2 may serve as a novel prognostic marker of Ewing sarcoma.

Key words: Ki-67, Ewing sarcoma, Immunohistochemistry, Prognosis, Enhancer of zeste homolog 2, Clinicopathology

中图分类号:

R574

张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.

ZHANG Xiying, ZHAI Chunyan, LI Jingsong, HAN Bo. Expression of EZH2 in Chinese Ewing sarcoma patients and its relationship with clinicopathological parameters and prognosis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 84-91.

参考文献

[1] Surdez D, Benetkiewicz M, Perrin V, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth[J]. Cancer Res, 2012, 72(17): 4494-4503.
[2] Borinstein SC, Beeler N, Block JJ, et al. A decade in banking ewing sarcoma: a report from the Childrens oncology group[J]. Front Oncol, 2013, 3: 57. doi:10.3389/fonc.2013.00057.
[3] Paulussen M, Bielack S, Jurgens H, et al. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up[J]. Ann Oncol, 2009, 20(Suppl 4): 140-142.
[4] Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2[J]. Cancer Cell, 2010, 18(2): 185-197.
[5] Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer[J]. Int J Biol Sci, 2012, 8(1): 59-65.
[6] Tang SH, Huang HS, Wu HU, et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo[J]. Oncotarget, 2014, 5(21): 10342-10355.
[7] Rhodes DR, Sanda MG, Otte AP, et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer[J]. J Natl Cancer Inst, 2003, 95(9): 661-668.
[8] Crea F, Hurt EM, Farrar WL. Clinical significance of Polycomb gene expression in brain tumors[J]. Mol cancer, 2010, 9: 265. doi: 10.1186/1476-4598-9-265.
[9] Benard A, Goossens-Beumer IJ, Van Hoesel AQ, et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer[J]. PLoS One, 2014, 9(9): 108265. doi: 10.1371/journal.pone.0108265.
[10] Chen DL, Zhang DS, Lu YX, et al. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer[J]. Oncotarget, 2015, 6(13): 10868-10879.
[11] Liu H, Liu Y, Liu W, et al. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma[J]. Nat Commun, 2015, 6:8494. doi: 10.1038/ncomms 9494.
[12] 刘宝岳, 杨郁, 杜娟, 等. EWS易等位分离探针荧光原位杂交和免疫组织化学抗体(FLI-1和CD99)在尤文肉瘤/原始神经外胚层肿瘤诊断中的价值[J]. 北京大学学报(医学版), 2008, 40(4): 358-362. LIU Baoyue, YANG Yu, DU Juan, et al. Application of the in situ hybridization with EWS dual-color break-apart fluorescence probe and anti-CD99 and anti-FIL-1 antibodies in the diagnosis of Ewing sarcoma/primitive neuroectodermal tumor[J]. Journal of Peking University(Health Sciences), 2008, 40(4): 358-362.
[13] Lin YW, Ren LL, Xiong H, et al. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer[J]. J Pathol, 2013, 230(3): 277-290.
[14] Zhu Q, Zhang L, Li X, et al. Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia[J]. Tumour Biol, 2016, 37(8): 11409-11420.
[15] 董玉兰, 杨向红, 高英贤, 等. Ki-67及p53蛋白在口腔鳞状上皮肿瘤中的表达及意义[J]. 中国医科大学学报, 2002, 31(2): 16-17. DONG Yulan, YANG Xianghong, GAO Yingxian, et al. Expression of Ki-67 and p53 in oral squamous epithelial tumor and its significance[J]. J Chin Med Univ, 2002, 31(2): 16-17.
[16] Lu N, Lin T, Wang L, et al. Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma[J]. Tumour Biol, 2015, 36(5): 3843-3852.
[17] Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors[J]. Cancer Cell, 2007, 11(5): 421-429.
[18] Von Levetzow C, Jiang X, Gwye Y, et al. Modeling initiation of Ewing sarcoma in human neural crest cells[J]. PLoS One, 2011, 6(4): 19305. doi: 10.1371/journal. pone.0019305.
[19] Selvanathan SP, Graham GT, Erkizan HV, et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing[J]. PNAS, 2015, 112(11): 1307-1316.
[20] Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life[J]. Nature, 2011, 469(7330): 343-349.
[21] Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex[J]. Mol Cell, 2004, 15(1): 57-67.
[22] Montgomery ND, Yee D, Chen A, et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation[J]. Curr Biol, 2005, 15(10): 942-947.
[23] Kim KH, Roberts CW. Targeting EZH2 in cancer[J]. Nat Med, 2016, 22(2): 128-134.
[24] Richter GH, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation[J]. Proc Natl Sci U S A, 2009, 106(13): 5324-5329.
[25] Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets[J]. Cancer Res, 2004, 64(22): 8213-8221.
[26] Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewings sarcoma initiation program in primary human mesenchymal stem cells[J]. Cancer Res, 2008, 68(7): 2176-2185.
[27] Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer[J]. EMBO J, 2003, 22(20): 5323-5335.
[28] Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol, 1984, 133(4): 1710-1715.
[29] Lopez-Guerrero JA, Machado I, Scotlandi K, et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewings sarcoma family of tumors[J]. Int J Cancer, 2011, 128(5): 1139-1150.
[30] Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer[J]. Cancer Sci, 2006, 97(6): 484-491.
[31] Huqun, Ishikawa R, Zhang J, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer[J]. Cancer, 2012, 118(6): 1599-1606.

相关文章 15

[1]	栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51.
[2]	史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52.
[3]	路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124.
[4]	李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报（医学版）, 2017, 55(9): 73-78.
[5]	宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(7): 12-16.
[6]	孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.
[7]	董尧,宋亚林,田涛,高建国. 确诊8年未经治疗却无明显进展的阴茎恶性黑色素瘤1例报道[J]. 山东大学学报（医学版）, 2017, 55(3): 125-126.
[8]	林家香,郭子嘉,苏鹏,王晓,郭雅欣,吴晓娟,相磊,周志强, 王妍,崔秀杰,潘爱凤,郭成浩. 致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力[J]. 山东大学学报（医学版）, 2017, 55(3): 100-106.
[9]	周兰兰,潘学谊,郭煜. 48例急性混合细胞表型白血病患者的临床特征及预后[J]. 山东大学学报（医学版）, 2017, 55(2): 79-83.
[10]	刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(10): 84-89.
[11]	李晓宁,崔连群. 急性心肌梗死合并多支血管病变患者非梗死相关动脉处理的时机[J]. 山东大学学报（医学版）, 2016, 54(8): 50-54.
[12]	王雯,刘尧,龙飞,马卫霞,苏莉莉. 外周血淋巴细胞/单核细胞比值与恶性胸膜间皮瘤患者预后的关系[J]. 山东大学学报（医学版）, 2016, 54(8): 72-77.
[13]	刘童,张欣,王传新. IRX5 mRNA在结直肠癌诊断及预后中的价值[J]. 山东大学学报（医学版）, 2016, 54(7): 69-74.
[14]	马琳,张冬,唐蕾,叶嗣源,焉传祝,曹丽丽. 肌萎缩侧索硬化预后相关的血液学标志物[J]. 山东大学学报（医学版）, 2016, 54(4): 46-50.
[15]	徐志宏,吴小华,姚铁柱,王晓翔,段晓阳,史健. mir-99a的表达与上皮性卵巢癌患者预后的关系[J]. 山东大学学报（医学版）, 2016, 54(3): 77-80.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed